Buy lipid-lowering medication online — atorvastatin, rosuvastatin, simvastatin, pitavastatin, ezetimibe, fenofibrate and cholestyramine — for primary and secondary cardiovascular prevention. High cholesterol (elevated LDL-C and non-HDL-C) is a leading modifiable driver of myocardial infarction, ischaemic stroke, and peripheral arterial disease. The 2019 ESC/EAS, 2018 AHA/ACC, and 2025 ACC/AHA lipid guidelines centre LDL-C reduction as the primary intervention — each 1 mmol/L (~38 mg/dL) drop in LDL-C reduces cardiovascular events by 20–25% across primary prevention, secondary prevention, diabetes, CKD, and post-stroke populations. Choice of agent depends on baseline LDL-C, ASCVD risk, statin tolerance, triglyceride burden, and pregnancy status.High-intensity statins (≥50% LDL-C reduction). Atorvatin (atorvastatin 5 mg) and Lipvas (atorvastatin) cover the lipophilic CYP3A4-cleared workhorse — Lipitor's molecule, first-line for secondary prevention at 40–80 mg. Rosuvastatin counterparts Crestor, Rozucor, Rosu HDL, and Rosuline deliver the largest LDL drop per milligram (rosuvastatin 20 mg ≈ atorvastatin 40 mg) with hydrophilic kinetics and minimal CYP3A4 interaction — preferred when the patient takes CYP3A4 inhibitors (clarithromycin, diltiazem, antifungals) or has had statin-related muscle symptoms on atorvastatin.Moderate-intensity statins (30–49% LDL-C reduction) for primary prevention or statin-intolerant patients. Simvastatin pages Simvatic, Simlo 5, Sim HDL, and Simvotin cover the original 1990s statin (FDA 2011 myopathy alert capped 80 mg). Pivasta (pitavastatin) is the newest molecule, glucuronidated rather than CYP-cleared — the lipid drug of choice for transplant patients on cyclosporine, where most statins are contraindicated.Non-statin add-ons and alternatives. Ezedoc (ezetimibe 10 mg) blocks intestinal cholesterol absorption via NPC1L1 inhibition — adds ~24% LDL drop on top of any statin (IMPROVE-IT trial cardiovascular benefit). Lipicard (fenofibrate) is the PPAR-α agent: drops triglycerides 30–50% and is first choice for severe hypertriglyceridaemia (>500 mg/dL pancreatitis risk) or mixed dyslipidaemia. Choltran Sachet (cholestyramine) is the bile-acid-sequestrant option for statin-intolerant patients, paediatric familial hypercholesterolaemia, cholestatic pruritus, and bile-acid diarrhoea — non-absorbed, pregnancy-compatible.How to choose. ASCVD ≥7.5% 10-year risk or established cardiovascular disease → high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg). LDL-C still above goal at maximally tolerated statin → add ezetimibe. Triglycerides >500 mg/dL → fenofibrate first (pancreatitis prevention), then statin. Pregnancy → cholestyramine (the only lipid drug compatible with pregnancy — statins absolutely contraindicated). Transplant on cyclosporine, or pre-existing transaminitis → pitavastatin.All MedsBase lipid-lowering medications are FDA-approved generics manufactured by WHO-GMP certified producers. Worldwide shipping. Loyalty points apply on every order.
2026 buyer’s guide: See our shortlist Best Cholesterol Medications 2026 for ranked picks, comparison table, dosing notes and decision shortcut.